Hyphens Pharma International Limited announced on Oct, 16 2025 that its wholly owned unit, Hyphens Pharma Pte. Ltd., has expanded its partnership with Medac Gesellschaft für klinische Spezialpräparate m.b.H. to cover Thailand and Cambodia for the commercialisation of the Metoject® subcutaneous autoinjector pen.

The latest arrangement enlarges a deal signed in Mar, 2025, which had given Hyphens exclusive rights to register and market the product in Singapore, Malaysia, the Philippines and Vietnam.

Metoject® is already authorised in more than 15 countries across Europe, the United States and Japan, and is recognised as a first-line treatment for rheumatoid arthritis under European and American guidelines. The methotrexate‐based injection is also indicated for plaque psoriasis, offering higher bioavailability and fewer gastrointestinal side effects compared with oral methotrexate.

Hyphens stated that the agreement’s extension is not expected to materially affect the group’s net tangible assets or earnings per share for the current financial year.